News All Media Coverage News Media Coverage StemCyte Announces FDA Clearance of Expanded Access Program for RegeneCyte® (HPC, Cord Blood) to Address Unmet Need in Long COVID More → Media Coverage StemCyte Introduces Insurance-Linked Cord Blood Access in Taiwan More → Media Coverage StemCyte Launches First Insurance-Linked Public Cord Blood Access in Taiwan, Setting a New Standard in Cell Therapy Protection More → Media Coverage StemCyte Announces Successful Phase IIa Clinical Trial Results for HPC, Cord Blood in Treating Post-COVID Syndrome: 85% of Patients Experience Complete Relief from Fatigue Symptoms More → Media Coverage U.S. FDA Approves StemCyte Biologics License Application for REGENECYTE™ Cord Blood Cell Therapy Product More → Media Coverage StemCyte’s HPC Cord Blood Receives RMAT Designation for Long COVID-19 Treatment More → Media Coverage StemCyte Renews Contract with the California State Umbilical Cord Blood Collection Program More → Media Coverage Interview with StemCyte CEO Tong-Young Lee PhD More → Media Coverage StemCyte signs a cooperation agreement with a cutting-edge US immune cell therapy company to supply drug preparation raw materials for allogeneic modified cell therapy More → Media Coverage The first Post-COVID Syndrome Phase II clinical trial has begun recruiting patients. More →
